Royal London Asset Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $604M | Sell |
656,585
-83,249
| -11% | -$84.4M | 1.27% | 11 |
|
|
2025
Q4 | $795M | Sell |
739,834
-5,517
| -0.7% | -$5.28M | 1.67% | 9 |
|
|
2025
Q3 | $569M | Buy |
745,351
+39,608
| +6% | +$29.5M | 1.22% | 11 |
|
|
2025
Q2 | $550M | Sell |
705,743
-72,351
| -9% | -$56.2M | 1.26% | 10 |
|
|
2025
Q1 | $643M | Buy |
778,094
+36,800
| +5% | +$30.6M | 1.52% | 10 |
|
|
2024
Q4 | $572M | Buy |
741,294
+18,925
| +3% | +$15.7M | 1.4% | 10 |
|
|
2024
Q3 | $640M | Sell |
722,369
-62,981
| -8% | -$56.6M | 1.58% | 10 |
|
|
2024
Q2 | $711M | Sell |
785,350
-64,296
| -8% | -$51.4M | 1.82% | 8 |
|
|
2024
Q1 | $661M | Sell |
849,646
-40,555
| -5% | -$28.9M | 1.65% | 8 |
|
|
2023
Q4 | $519M | Sell |
890,201
-15,231
| -2% | -$8.89M | 1.48% | 8 |
|
|
2023
Q3 | $487M | Sell |
905,432
-361,200
| -29% | -$186M | 1.58% | 8 |
|
|
2023
Q2 | $593M | Buy |
1,266,632
+111,000
| +10% | +$46.6M | 1.92% | 8 |
|
|
2023
Q1 | $397M | Buy |
1,155,632
+68,611
| +6% | +$23.1M | 1.59% | 9 |
|
|
2022
Q4 | $398M | Buy |
1,087,021
+169,047
| +18% | +$59.9M | 1.78% | 8 |
|
|
2022
Q3 | $297M | Sell |
917,974
-20,915
| -2% | -$6.63M | 1.5% | 9 |
|
|
2022
Q2 | $305M | Buy |
938,889
+102,433
| +12% | +$30.7M | 1.41% | 10 |
|
|
2022
Q1 | $240M | Buy |
836,456
+18,522
| +2% | +$4.77M | 0.94% | 18 |
|
|
2021
Q4 | $226M | Buy |
817,934
+9,765
| +1% | +$2.48M | 0.84% | 21 |
|
|
2021
Q3 | $187M | Sell |
808,169
-96,492
| -11% | -$23.8M | 0.76% | 26 |
|
|
2021
Q2 | $208M | Buy |
904,661
+27,756
| +3% | +$5.58M | 0.85% | 20 |
|
|
2021
Q1 | $164M | Buy |
876,905
+27,483
| +3% | +$5.38M | 0.75% | 27 |
|
|
2020
Q4 | $143M | Buy |
849,422
+22,280
| +3% | +$3.33M | 0.75% | 25 |
|
|
2020
Q3 | $121M | Buy |
827,142
+144,349
| +21% | +$22.3M | 0.73% | 24 |
|
|
2020
Q2 | $111M | Sell |
682,793
-14,564
| -2% | -$2.24M | 0.78% | 21 |
|
|
2020
Q1 | $96.5M | Buy |
697,357
+763
| +0.1% | +$105K | 0.78% | 21 |
|
|
2019
Q4 | $91.5M | Buy |
696,594
+14,720
| +2% | +$1.71M | 0.63% | 29 |
|
|
2019
Q3 | $76.2M | Buy |
681,874
+2,816
| +0.4% | +$314K | 0.58% | 34 |
|
|
2019
Q2 | $75.2M | Buy |
679,058
+31,832
| +5% | +$3.75M | 0.71% | 29 |
|
|
2019
Q1 | $84M | Sell |
647,226
-24,934
| -4% | -$3.03M | 0.66% | 27 |
|
|
2018
Q4 | $76.8M | Buy |
672,160
+154,323
| +30% | +$17.2M | 0.67% | 26 |
|
|
2018
Q3 | $55.6M | Sell |
517,837
-7,218
| -1% | -$722K | 0.57% | 36 |
|
|
2018
Q2 | $44.8M | Buy |
+525,055
| New | +$43.1M | 0.45% | 49 |
|
|
2016
Q2 | $30.8M | Sell |
391,617
-17,195,178
| -98% | -$1.29B | 0.5% | 45 |
|
|
2016
Q1 | $244K | Buy |
17,586,795
+17,186,195
| +4,290% | +$1.3B | 0.35% | 62 |
|
|
2015
Q4 | $34.5M | Sell |
400,600
-481
| -0.1% | -$39.9K | 0.53% | 41 |
|
|
2015
Q3 | $33.6M | Buy |
+401,081
| New | +$33.9M | 0.54% | 40 |
|
|
2014
Q4 | $292K | Buy |
418,748
+73,624
| +21% | +$4.97M | 0.55% | 43 |
|
|
2014
Q3 | $22.5M | Buy |
345,124
+12,764
| +4% | +$808K | 0.57% | 42 |
|
|
2014
Q2 | $20.3M | Sell |
332,360
-3,754
| -1% | -$224K | 0.47% | 47 |
|
|
2014
Q1 | $20M | Buy |
336,114
+90,179
| +37% | +$5.03M | 0.46% | 49 |
|
|
2013
Q4 | $12.8M | Buy |
245,935
+2,497
| +1% | +$125K | 0.32% | 72 |
|
|
2013
Q3 | $12.3M | Buy |
243,438
+2,626
| +1% | +$137K | 0.33% | 71 |
|
|
2013
Q2 | $12M | Buy |
+240,812
| New | +$13.1M | 0.35% | 63 |
|
Other funds holding LLY
VCM
VPM
Royal London Asset Management's LLY Position: Q1 2026 in Review
Royal London Asset Management reduced its Eli Lilly (LLY) stake by 11% in Q1 2026, selling an estimated $84.4M and leaving 656,585 shares worth $604M. The position accounts for 1.27% of the portfolio, ranked #11.
Royal London Asset Management first reported a position in LLY in Q2 2013 and has held it in 43 quarters since. The position peaked at $795M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Royal London Asset Management held 656,585 shares of Eli Lilly worth $604M as of Q1 2026.
- Royal London Asset Management sold 83,249 Eli Lilly shares in Q1 2026, an estimated $84.4M.
- Eli Lilly made up 1.27% of Royal London Asset Management's portfolio in Q1 2026, its #11 holding.
- Royal London Asset Management first reported a position in Eli Lilly in Q2 2013 and has held it in 43 quarters since.
- Royal London Asset Management's Eli Lilly position peaked at $795M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Royal London Asset Management's 13F filing for Q1 2026, filed 1 May 2026.